Crumly & Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Crumly & Associates’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,839	Closed	-$450K	–	107
2022 Q1	$450K	Buy	5,839 +91	+2%	+$7.61K	0.17%	76
2021 Q4	$505K	Buy	5,748 +1,613	+39%	+$133K	0.2%	71
2021 Q3	$320K	Sell	4,135 -2,624	-39%	-$207K	0.15%	84
2021 Q2	$564K	Sell	6,759 -779	-10%	-$61.8K	0.27%	59
2021 Q1	$569K	Buy	7,538 +3,446	+84%	+$282K	0.33%	43
2020 Q4	$360K	Sell	4,092 -304	-7%	-$24.1K	0.25%	46
2020 Q3	$334K	Buy	+4,396	New	+$445K	0.29%	35

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Crumly & Associates's BMRN Position: Q2 2022 in Review

Crumly & Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 5,839 shares — an estimated $450K sold.

Crumly & Associates first reported a position in BMRN in Q3 2020 and held it in 7 quarters. The position peaked at $569K in Q1 2021. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Crumly & Associates reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Crumly & Associates sold 5,839 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $450K.
Crumly & Associates first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 7 quarters.
Crumly & Associates's BioMarin Pharmaceuticals position peaked at $569K in Q1 2021.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Crumly & Associates's 13F filing for Q2 2022, filed 1 Aug 2022.